Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Ordenar per
Keyphrases
Patient-reported Outcomes
100%
Randomized Double-blind
100%
Atogepant
100%
Preventive Migraine Treatment
100%
ADVANCE Trial
100%
Activity Impairment
58%
Migraine
50%
Role Functioning
41%
Diary
41%
Daily Activities
41%
Physical Impairment
41%
Placebo
33%
Treatment Duration
25%
Headache Impact Test-6 (HIT-6)
25%
Emotional Skills
16%
Preventive Effect
16%
Function Domain
16%
Group Performance
16%
Migraine Days
16%
Monthly Activity
16%
Beneficial Effects
8%
Clinically Significant
8%
Once-daily
8%
Between-group Difference
8%
Quality of Life Questionnaire
8%
Change from Baseline
8%
Placebo-controlled
8%
Preventive Treatment
8%
Parallel Trials
8%
Episodic Migraine
8%
Least Mean Square
8%
Intent-to-treat
8%
Calcitonin Gene-related Peptide
8%
Health-related Quality of Life Measures
8%
Migraine Prevention
8%
Migraine-Specific Quality of Life
8%
Medicine and Dentistry
Migraine Treatment
100%
Atogepant
100%
Patient-Reported Outcome
100%
Migraine
83%
Physical Disease
41%
Placebo
41%
Headache
25%
Intention-to-Treat Analysis
8%
Episodic Migraine
8%
Group Trial
8%
Quality of Life Measure
8%
Quality of Life
8%
Calcitonin Gene-Related Peptide Receptor Antagonist
8%
Oral
8%
Least Squares Method
8%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Atogepant
100%
Placebo
41%
Physical Disease
41%
Headache
25%
Group Trial
8%
Episodic Migraine
8%
Calcitonin Gene Related Peptide Receptor Antagonist
8%
Neuroscience
Migraine
100%
Placebo
41%
Headache
25%
Quality of Life
16%
Calcitonin Gene-Related Peptide Receptor Antagonist
8%